media/financial: (OvPlex™) HealthLinx confirms potential of novel biomarker in predicting ovarian cancer outcome - Proactiveinvestors (AU)

HealthLinx confirms potential of novel biomarker in predicting ovarian cancer outcome

HealthLinx Releases Initial Results from First Stage of 1,150-Subject OvPlex Study | ProteoMonitor | Proteomics | GenomeWeb

HealthLinx reports solid data from OvPlex study - ovarian cancer, medical diagnostics - Australian Life Scientist

media: Doctor ordered to keep silent on company's ovarian cancer test - Healthlinx/OvPlex/Professor Quinn

Ovarian cancer test comes under fire (OvPlex/Healthlinx/Australia) media article

OvPlex also available (according to article) in Britain/Singapore

Arrayit Signs on Docro to Help Ovarian Cancer Diagnostic Gain FDA Clearance GenomeWeb

Vermillion's OVA1 became the first protein-based in vitro diagnostic multivariate index assay to receive FDA clearance [See PM 09/17/09] and earlier this month it and Quest Diagnostics began marketing OVA1.

In addition, Correlogic is in discussions with the FDA about its OvaCheck test,

and

Healthlinx, which launched its test called OvPlex in the UK in February, has said that it may launch the test in the US next year, if it receives regulatory approval.

This week, Arrayit said that OvaDx will be the market's first "comprehensive diagnostic for ovarian cancer" and will be targeted to all women over the age of 35.

Financial news: HealthLinx Ltd launches ovarian cancer OvPlex™ test into UK market

HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex™ on 25 February 2010.
The company obtained European Certification for OvPlex™ paving the way to market and sell the product within the European community.

PharmaLive press release: Clinical Science to publish manuscript on HTX005 ovarian cancer biomarker 'OvPlex' (plus HTX005/AGR2)

Note: the abstract included here did not indicate the number of patients involved in the studies (see prior research articles) but according to the press release showed results in stages 11/111.

"10 February 2010, Melbourne: HealthLinx Limited (ASX:HTX) has been notified by the journal Clinical Science that a manuscript submitted for review by HealthLinx scientists and collaborators at the University of Liverpool has been accepted for publication. The manuscript describes the identification of HTX005 (AGR2) as a novel biomarker released into the bloodstream of ovarian cancer patients.

The performance of the novel biomarker AGR2 will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data it is expected that this biomarker will increase the performance of OvPlex™ to greater than 97 per cent."